Clinical Trial Update: The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing PF-03654764 with or without fexofenadine (Allegra) for allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Allegra (fexofenadine)
• PF-03654764

Snippet

Sponsor: Pfizer | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED